
Bing Xia, MD, assistant professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the frontline treatment landscape of ALK-positive non–small cell lung cancer (NSCLC).

Your AI-Trained Oncology Knowledge Connection!


Published: May 22nd 2019 | Updated: